Related Experiment Videos
[Recombinant replication-defective adenovirus based rabies vaccine]
Wen-hui Li1, Yun Zhang, Shu-hui Wang
1Department of Etiology, Institute of Basic Medical Science, CAMS and PUMC, Beijing 100005, China.
Summary
Recombinant adenoviruses carrying the rabies virus glycoprotein gene were successfully constructed and demonstrated significant protection in mice against lethal rabies challenge. These findings highlight their potential as novel rabies vaccines.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Context:
- Rabies virus poses a significant public health threat globally.
- Developing effective and safe rabies vaccines is crucial for disease prevention.
- Recombinant viral vectors offer a promising platform for vaccine development.
Purpose:
- To construct and characterize recombinant adenoviruses encoding the glycoprotein (GP) gene of the high neuropathogenicity rabies virus CVS-N2C strain.
- To evaluate the efficacy of these recombinant adenoviruses as potential rabies vaccines in a mouse model.
Summary:
- Recombinant adenoviruses (rAdGPcvs and rAdGPcvs') were generated using the pAdEasy system and confirmed via molecular techniques including cDNA sequencing, Northern blot, Dot blot, and Western blot.
- The recombinant adenoviruses exhibited typical characteristics, stable genomes, and successfully expressed rabies virus GP with a molecular mass of 66,000 Da.
- Immunization with rAdGPcvs and rAdGPcvs' in mice resulted in significant survival rates (87.5%-100% and 73.3%-83.3%, respectively) following a lethal intracerebral rabies challenge, whereas control groups succumbed.
Impact:
- This study presents the first adenoviral recombinants based on the high neuropathogenicity rabies CVS-N2C glycoprotein.
- The developed recombinant adenoviruses show considerable promise for the development of next-generation rabies vaccines.
- Successful immunization offers a potential new strategy for rabies prevention and control.